VNRX (VolitionRX) Other Stockholders Equity: $-0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VNRX VolitionRX Ltd VNRX
54 GF Score
Price $0.58
GF Value $17.52
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is VolitionRX Other Stockholders Equity?

VolitionRX VNRX +71.82% 54 Other Stockholders Equity is $-0.00 Mil as of Jun. 2026. GuruFocus rates VNRX with a GF Score™ of 54/100 and a GF Value™ of $17.52 (Possible Value Trap). The stock has 8 warning signs investors should review.

VolitionRX's Other Stockholders Equity for the quarter that ended in Jun. 2026 was $-0.00 Mil.

VolitionRX's quarterly Other Stockholders Equity declined from Dec. 2025 ($-0.00 Mil) to Mar. 2026 ($-0.00 Mil) and declined from Mar. 2026 ($-0.00 Mil) to Jun. 2026 ($-0.00 Mil).

VolitionRX's annual Other Stockholders Equity declined from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($-0.00 Mil) but then increased from Dec. 2024 ($-0.00 Mil) to Dec. 2025 ($-0.00 Mil).

VolitionRX Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for VolitionRX's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

VolitionRX Other Stockholders Equity Chart

VolitionRX Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.00 -0.00

VolitionRX Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.00 -0.00 -0.00 -0.00
VNRX
54GF Score
VolitionRX Ltd VNRX
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

VolitionRX Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $-0.00 Mil mean?
VolitionRX (VNRX) has a Other Stockholders Equity of $-0.00 Mil as of Jun. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on VolitionRX and its competitors.
Is VolitionRX's Other Stockholders Equity too high?
VolitionRX's current Other Stockholders Equity is $-0.00 Mil. Overall, VolitionRX has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does VolitionRX's Other Stockholders Equity compare to ALRTF and ADGM?
VolitionRX's Other Stockholders Equity of $-0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Medical Devices & Instruments company?
A good Other Stockholders Equity depends on the Medical Devices & Instruments industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on VolitionRX and its competitors. VolitionRX's current Other Stockholders Equity is $-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VolitionRX stock overvalued right now?
Based on GuruFocus' analysis, VolitionRX (VNRX) is currently considered Possible Value Trap. The stock's GF Value™ is $17.52, compared to a current price of $0.58 — trading 96.7% below its estimated fair value. The current Other Stockholders Equity is $-0.00 Mil. VolitionRX's overall GF Score™ is 54/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For VolitionRX (VNRX), the current Other Stockholders Equity is $-0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is VolitionRX (VNRX) Overvalued in 2026?

Based on GuruFocus' analysis, VolitionRX stock appears to be undervalued. The current stock price of $0.58 is trading 96.7% below its estimated GF Value™ of $17.52. GuruFocus considers VolitionRX to be Possible Value Trap.

Key valuation signals for VNRX:

  • Other Stockholders Equity: $-0.00 Mil
  • GF Value™: $17.52 vs. price of $0.58 (96.7% below fair value)
  • GF Score™: 54/100 with 8 warning signs

No single metric tells the full story. See the VNRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

VolitionRX Business Description

Address 1489 West Warm Springs Road, Suite 110, Henderson, NV, USA, 89014
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring.
54GF Score

Get the complete analysis for VNRX

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.58
Price
$17.52
GF Value